GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cartesian Therapeutics Inc (NAS:RNAC) » Definitions » 5-Year Yield-on-Cost %

Cartesian Therapeutics (Cartesian Therapeutics) 5-Year Yield-on-Cost % : 0.00 (As of May. 06, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cartesian Therapeutics 5-Year Yield-on-Cost %?

Cartesian Therapeutics's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for Cartesian Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



RNAC's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.895
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Cartesian Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Cartesian Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cartesian Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Cartesian Therapeutics's 5-Year Yield-on-Cost % falls into.



Cartesian Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Cartesian Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Cartesian Therapeutics  (NAS:RNAC) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Cartesian Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Cartesian Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cartesian Therapeutics (Cartesian Therapeutics) Business Description

Traded in Other Exchanges
Address
65 Grove Street, Watertown, MA, USA, 02472
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.
Executives
Carsten Brunn director, officer: President & CEO C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Peter G Traber officer: Chief Medical Officer 430 THAMER LANE, HOUSTON TX 77025
Takashi Kei Kishimoto officer: Chief Scientific Officer 480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Lloyd P. Johnston officer: COO and SVP, R&D 480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Blaine Davis officer: Chief Financial Officer C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Carrie Smith Cox director SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Timothy C Barabe director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Timothy A Springer director 36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Kevin Tan officer: Chief Financial Officer 20 HICKORY ROAD, WELLESLEY MA 02482
Nishan M Desilva director 11119 NORTH TORREY PINES RD STE 200, LA JOLLA CA 92037
Ann K. Donohue officer: VP Finance C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, BUILDING ONE, WATERTOWN MA 02472
Bradford D. Dahms officer: Chief Financial Officer C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Goran Ando director
Scott Dunseth Myers director C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Elona Esq. Kogan officer: General Counsel C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065

Cartesian Therapeutics (Cartesian Therapeutics) Headlines

From GuruFocus

Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference

By Stock market mentor Stock market mentor 02-07-2023

Selecta Biosciences Announces $38.7 Million Underwritten Offering

By GuruFocusNews GuruFocusNews 04-06-2022